Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Immucell ( (ICCC) ) is now available.
On June 25, 2025, ImmuCell Corporation announced the commencement of its CEO succession planning process as current CEO Michael F. Brigham plans to retire by early 2026. The company has begun the search for a new CEO, with the goal of selecting a candidate by the end of the year. Brigham, who has been with ImmuCell since 1989 and served as CEO since 2000, will assist in the transition and continue to serve on the Board of Directors through June 2026. This transition marks a significant moment for ImmuCell as it seeks leadership to continue its growth and innovation in the animal health industry.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
Immucell’s overall stock score reflects strong sales growth and operational improvements, particularly in cash flow and production capacity. Technical indicators suggest positive momentum, but the negative P/E ratio and ongoing FDA approval challenges weigh on the valuation. The recent appointment of an experienced CFO is a positive corporate event, expected to support future growth.
To see Spark’s full report on ICCC stock, click here.
More about Immucell
ImmuCell Corporation is a growing animal health company that develops, manufactures, and markets scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. The company produces First Defense, which provides immediate immunity to newborn calves, and is developing Re-Tain, a treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.
Average Trading Volume: 29,336
Technical Sentiment Signal: Buy
Current Market Cap: $60.1M
See more insights into ICCC stock on TipRanks’ Stock Analysis page.